BioCentury
ARTICLE | Company News

Sarepta launches Exondys 51 managed access program

July 19, 2017 8:32 PM UTC

Sarepta Therapeutics Inc. (NASDAQ:SRPT) and Clinigen Group plc (LSE:CLIN) launched a managed access program for Exondys 51 eteplirsen to treat Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping.

The program will allow physicians to prescribe Exondys 51 to patients that meet pre-specified criteria when funding can be secured. The partners are first conducting the program in certain European, North and South American countries where Exondys 51 is not approved, and Sarepta said it plans to expand the program to more countries...

BCIQ Target Profiles

Dystrophin